2 Stocks to Buy No Matter What Happens in March
Keep your eyes on the prize.
Vertex Pharmaceuticals(VRTX)
Nasdaq Global Select
VRTX
$236.48
-$5.45
-2.3%
Price as of March 11, 2022, 4:00 p.m. ET
View Interactive VRTX Charts
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
Interactive Chart
Compare VRTX Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals
|
$236.48 | $60B | 9.9% | 154.4% |
|
ILMN |
$303.87 | $48B | -26.4% | 82.1% |
|
EXEL |
$20.99 | $7B | -8.0% | -3.9% |
|
GILD |
$58.00 | $73B | -4.1% | 1.9% |
|
BMY |
$68.87 | $150B | 17.8% | 40.7% |
News & Analysis: Vertex Pharmaceuticals
The Fool has written over 700 articles on Vertex Pharmaceuticals.
3 Top Biotech Stocks to Buy for the Long Haul
They're already bringing in billions of dollars in revenue.
Why Investors Should Be Watching Vertex Pharmaceuticals
The company has several big opportunities on the horizon.
These Safe Stocks Can Succeed in a Higher Interest Rate Environment
These companies are stable picks for investors seeking to generate long-term portfolio value.
Is this Beaten-Down Biotech Making a Comeback?
It's climbed 15% since the start of the year.
My Top Growth Stock to Buy in February
Despite recent issues, Vertex Pharmaceuticals' long-term thesis is intact.
Here's What to Know About Vertex Pharmaceuticals' Earnings Report
Its plan to diversify into new therapy areas is continuing to take shape.
Market Dip? Here's Why This Bargain Biotech Is a Smart Buy Now
This company is a market leader -- and business is growing.
Vertex Pharmaceuticals (VRTX) Q4 2021 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2021.
Better Buy: Vertex Pharmaceuticals vs. Biogen
In this battle of biotech giants, one emerges as the clear winner.
